At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
Human Amniotic Fluidbiological
Likely dose
Human Amniotic Fluid 10mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Randomized Double-blinded Placebo-controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients
In Brief
A Phase 2 clinical trial evaluating Human Amniotic Fluid for SARS CoV-2. Completed, enrolled 47 participants across 1 site.
Detailed Summary
The purpose of this study is to explore the effectiveness of processed human amniotic fluid as a treatment for COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS CoV-2
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartOct 2020
Primary CompletionAug 2022
Study CompletionFeb 2023
TodayJul 2026
First PostedAug 4, 2020
Enrollment StartOct 28, 2020
Primary CompletionAug 2, 2022
Study CompletionFeb 15, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.9 years ago
Interventions
Human Amniotic Fluidbiological
Patients will receive 10ml intravenous hAF each day for 5 consecutive days.